Literature DB >> 21737559

Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.

D B Sprunger1, A L Olson, T J Huie, E R Fernandez-Perez, A Fischer, J J Solomon, K K Brown, J J Swigris.   

Abstract

Recent epidemiological studies have suggested an increased risk of venous thromboembolism (VTE) in lung fibrosis. Large-scale epidemiological data regarding the risk of VTE in pulmonary fibrosis-associated mortality have not been published. Using data from the National Center for Health Statistics from 1988-2007, we determined the risk of VTE in decedents with pulmonary fibrosis in the USA. We analysed 46,450,489 records, of which 218,991 met our criteria for idiopathic pulmonary fibrosis. Among these, 3,815 (1.74%) records also contained a diagnostic code for VTE. The risk of VTE in pulmonary fibrosis decedents was 34% higher than in the background population, and 44% and 54% greater than among decedents with chronic obstructive pulmonary disease and lung cancer, respectively. Those with VTE and pulmonary fibrosis died at a younger age than those with pulmonary fibrosis alone (females: 74.3 versus 77.4 yrs (p<0.0001); males: 72.0 versus 74.4 yrs (p<0.0001)). Decedents with pulmonary fibrosis had a significantly greater risk of VTE. Those with VTE and pulmonary fibrosis died at a younger age than those with pulmonary fibrosis alone. These data suggest a link between a pro-fibrotic and a pro-coagulant state.

Entities:  

Mesh:

Year:  2011        PMID: 21737559      PMCID: PMC3757572          DOI: 10.1183/09031936.00041411

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  26 in total

1.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

2.  Mortality rates from cryptogenic fibrosing alveolitis in seven countries.

Authors:  R Hubbard; I Johnston; D B Coultas; J Britton
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

3.  The epidemiology of interstitial lung diseases.

Authors:  D B Coultas; R E Zumwalt; W C Black; R E Sobonya
Journal:  Am J Respir Crit Care Med       Date:  1994-10       Impact factor: 21.405

4.  Rising mortality from cryptogenic fibrosing alveolitis.

Authors:  I Johnston; J Britton; W Kinnear; R Logan
Journal:  BMJ       Date:  1990-11-03

5.  Anticoagulant therapy for idiopathic pulmonary fibrosis.

Authors:  Hiroshi Kubo; Katsutoshi Nakayama; Masaru Yanai; Tomoko Suzuki; Mutsuo Yamaya; Mika Watanabe; Hidetada Sasaki
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

6.  Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003.

Authors:  Amy L Olson; Jeffrey J Swigris; Dennis C Lezotte; Jill M Norris; Carla G Wilson; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2007-05-03       Impact factor: 21.405

7.  Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse.

Authors:  M A Olman; N Mackman; C L Gladson; K M Moser; D J Loskutoff
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy.

Authors:  P D Stein; J W Henry
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

Review 9.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

10.  Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data.

Authors:  D M Mannino; R A Etzel; R G Parrish
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

View more
  33 in total

Review 1.  Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?

Authors:  Marios Panagiotou; Andrew J Peacock; Martin K Johnson
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 2.  Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Authors:  Boonphiphop Boonpheng; Patompong Ungprasert
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 3.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

Review 4.  Comprehensive Care of the Lung Transplant Patient.

Authors:  Ayodeji Adegunsoye; Mary E Strek; Edward Garrity; Robert Guzy; Remzi Bag
Journal:  Chest       Date:  2016-10-08       Impact factor: 9.410

5.  A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Authors:  Imre Noth; Kevin J Anstrom; Sara Bristol Calvert; Joao de Andrade; Kevin R Flaherty; Craig Glazer; Robert J Kaner; Mitchell A Olman
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

6.  Venous Thromboembolism After Adult Lung Transplantation: A Frequent Event Associated With Lower Survival.

Authors:  Manuel L Ribeiro Neto; Marie Budev; Daniel A Culver; C Randall Lane; Marcelo Gomes; Xiao-Feng Wang; Paulo Novis Rocha; Mitchell A Olman
Journal:  Transplantation       Date:  2018-04       Impact factor: 4.939

Review 7.  Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns.

Authors:  George Keramidas; Konstantinos I Gourgoulianis; Ourania S Kotsiou
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

8.  Management of Pulmonary Hypertension Due to Chronic Lung Disease.

Authors:  Jordan Sugarman; Jason Weatherald
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-07-01

Review 9.  Managing comorbidities in idiopathic pulmonary fibrosis.

Authors:  Blair G Fulton; Christopher J Ryerson
Journal:  Int J Gen Med       Date:  2015-09-22

10.  Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study.

Authors:  Federica Novelli; Tommaso Neri; Laura Tavanti; Chiara Armani; Concettina Noce; Fabio Falaschi; Maria Laura Bartoli; Federica Martino; Antonio Palla; Alessandro Celi; Pierluigi Paggiaro
Journal:  PLoS One       Date:  2014-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.